STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of reference products PROLIA® (denosumab) and XGEVA® (denosumab) respectively[1],[2]
NEW YORK,March 4,2025-- AIFIAN has released its 2024 Asia-Pacific investment report,highlighting key trends in liquor investment across the region. The findings reveal that Baijiu has emerged as the
NPT 2714 and NPT 2705 deliver increased network flexibility and investment protection TOKYO,March 4,2025--Ribbon Communications Inc. (Nasdaq: RBBN),a prominent supplier of real-time communications te
BEIJING,March 4,2025--A report from People\'s Daily: Lately,there has been much talk about foreign investors withdrawing from China on a large scale. Official data show that in 2024,foreign direct inv
BARCELONA,Spain,March 4,2025-- Fibocom (Stock code:300638),a global leading provider of AIoT solutions and wireless communication modules,has launchedQuickTaste AI,a collection of AI-powered solution
QNET\'s Award-Winning FinGreen Program Expands Financial Literacy Education Worldwide HONG KONG,March 5,2025-- Wellness and lifestyle direct selling company QNET\'s flagship financial literacy initiat
